1. Jin, Z.-B.; Gao, M.-L.; Deng, W.-L.; Wu, K.-C.; Sugita, S.; Mandai, M.; Takahashi, M. Stemming retinal regeneration with pluripotent stem cells. Prog. Retin. Eye Res. 2019, 69, 38–56. [CrossRef]
2. Kæstel, C.G.; Jørgensen, A.; Nielsen, M.; Eriksen, K.W.; Ødum, N.; Holst Nissen, M.; Röpke, C. Human Retinal Pigment Epithelial Cells Inhibit Proliferation and IL2R Expression of Activated T Cells. Exp. Eye Res. 2002, 74, 627–637. [CrossRef] [PubMed]
3. Wallace, C.A.; Moir, G.; Malone, D.F.G.; Duncan, L.; Devarajan, G.; Crane, I.J. Regulation of T-Lymphocyte CCL3 and CCL4 Production by Retinal Pigment Epithelial Cells. Investig. Opthalmology Vis. Sci. 2013, 54, 722–730. [CrossRef] [PubMed]
4. Sugita, S.; Kamao, H.; Iwasaki, Y.; Okamoto, S.; Hashiguchi, T.; Iseki, K.; Hayashi, N.; Mandai, M.; Takahashi, M. Inhibition of T-Cell Activation by Retinal Pigment Epithelial Cells Derived From Induced Pluripotent Stem Cells. Invest. Ophthalmol. Vis. Sci. 2015, 56, 1051–1062. [CrossRef] [PubMed]
5. Yan, F.; He, J.; Tang, L.; Kong, Y.; Shi, Y.; Chen, S.; Huang, Z. Transforming growth factor-β2 increases the capacity of retinal pigment epithelial cells to induce the generation of regulatory T cells. Mol. Med. Report. 2016, 13, 1367–1372. [CrossRef] [PubMed]
6. Idelson, M.; Alper, R.; Obolensky, A.; Yachimovich-Cohen, N.; Rachmilewitz, J.; Ejzenberg, A.; Beider, E.; Banin, E.; Reubinoff, B. Immunological Properties of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells. Stem Cell Rep. 2018, 11, 681–695. [CrossRef] [PubMed]
7. Liu, Y.; Xu, H.W.; Wang, L.; Li, S.Y.; Zhao, C.J.; Hao, J.; Li, Q.Y.; Zhao, T.T.; Wu, W.; Wang, Y.; et al. Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration. Cell Discov. 2018, 4, 50. [CrossRef]
8. Mandai, M.; Watanabe, A.; Kurimoto, Y.; Hirami, Y.; Morinaga, C.; Daimon, T.; Fujihara, M.; Akimaru, H.; Sakai, N.; Shibata, Y.; et al. Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration. N. Engl. J. Med. 2017, 376, 1038–1046. [CrossRef]
9. Mehat, M.S.; Sundaram, V.; Ripamonti, C.; Robson, A.G.; Smith, A.J.; Borooah, S.; Robinson, M.; Rosenthal, A.N.; Innes, W.; Weleber, R.G.; et al. Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration. Ophthalmology 2018, 125, 1765–1775. [CrossRef]
10. Sugita, S.; Mandai, M.; Hirami, Y.; Takagi, S.; Maeda, T.; Fujihara, M.; Matsuzaki, M.; Yamamoto, M.; Iseki, K.; Hayashi, N.; et al. HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration. J. Clin. Med. 2020, 9, 2217. [CrossRef]
11. Toosy, A.T.; Mason, D.F.; Miller, D.H. Optic neuritis. Lancet Neurol. 2014, 13, 83–99. [CrossRef]
12. Weinreb, R.N.; Aung, T.; Medeiros, F.A. The Pathophysiology and Treatment of Glaucoma. JAMA 2014, 311, 1901–1911. [CrossRef] [PubMed]
13. Jonas, J.B.; Aung, T.; Bourne, R.R.; Bron, A.M.; Ritch, R.; Panda-Jonas, S. Glaucoma. Lancet 2017, 390, 2183–2193. [CrossRef]
14. Miltner, A.M.; La Torre, A. Retinal Ganglion Cell Replacement: Current Status and Challenges Ahead. Dev. Dyn. 2018, 248, 118–128. [CrossRef]
15. Quigley, H.A. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 2006, 90, 262–267. [CrossRef]
16. Lee, J.; Choi, S.H.; Kim, Y.B.; Jun, I.; Sung, J.J.; Lee, D.R.; Kim, Y.I.; Cho, M.S.; Byeon, S.H.; Kim, D.S.; et al. Defined Conditions for Differentiation of Functional Retinal Ganglion Cells From Human Pluripotent Stem Cells. Invest. Ophthalmol. Vis. Sci. 2018, 59, 3531–3542. [CrossRef]
17. Venugopalan, P.; Wang, Y.; Nguyen, T.; Huang, A.; Muller, K.J.; Goldberg, J.L. Transplanted neurons integrate into adult retinas and respond to light. Nat. Commun. 2016, 7, 10472. [CrossRef]
18. Suen, H.C.; Qian, Y.; Liao, J.; Luk, C.S.; Lee, W.T.; Ng, J.K.W.; Chan, T.T.H.; Hou, H.W.; Li, I.; Li, K.; et al. Transplantation of Retinal Ganglion Cells Derived from Male Germline Stem Cell as a Potential Treatment to Glaucoma. Stem Cells Dev. 2019, 28, 1365–1375. [CrossRef]
19. Hertz, J.; Qu, B.; Hu, Y.; Patel, R.D.; Valenzuela, D.A.; Goldberg, J.L. Survival and Integration of Developing and Progenitor-Derived Retinal Ganglion Cells following Transplantation. Cell Transplant. 2014, 23, 855–872. [CrossRef]
20. Cen, L.-P.; Ng, T.K.; Liang, J.-J.; Zhuang, X.; Yao, X.; Yam, G.H.-F.; Chen, H.; Cheung, H.S.; Zhang, M.; Pang, C.P. Human Periodontal Ligament-Derived Stem Cells Promote Retinal Ganglion Cell Survival and Axon Regeneration After Optic Nerve Injury. Stem Cells 2018, 36, 844–855. [CrossRef]
21. Wu, S.; Chang, K.-C.; Nahmou, M.; Goldberg, J.L. Induced Pluripotent Stem Cells Promote Retinal Ganglion Cell Survival After Transplant. Invest. Ophthalmol. Vis. Sci. 2018, 59, 1571–1576. [CrossRef]
22. Rocha, P.N.; Plumb, T.J.; Crowley, S.D.; Coffman, T.M. Effector mechanisms in transplant rejection. Immunol. Rev. 2003, 196, 51–64. [CrossRef] [PubMed]
23. Kinnear, G.; Jones, N.D.; Wood, K.J. Costimulation Blockade. Transplantation 2013, 95, 527–535. [CrossRef] [PubMed]
24. Marino, J.; Paster, J.; Benichou, G. Allorecognition by T Lymphocytes and Allograft Rejection. Front. Immunol. 2016, 7, 582. [CrossRef]
25. Odeberg, J.; Piao, J.-H.; Samuelsson, E.-B.; Falci, S.; Åkesson, E. Low immunogenicity of in vitro-expanded human neural cells despite high MHC expression. J. Neuroimmunol. 2005, 161, 1–11. [CrossRef]
26. Johansson, S.; Price, J.; Modo, M. Effect of Inflammatory Cytokines on Major Histocompatibility Complex Expression and Differentiation of Human Neural Stem/Progenitor Cells. Stem Cells 2008, 26, 2444–2454. [CrossRef]
27. Liu, J.; Götherström, C.; Forsberg, M.; Samuelsson, E.-B.; Wu, J.; Calzarossa, C.; Hovatta, O.; Sundström, E.; Åkesson, E. Human neural stem/progenitor cells derived from embryonic stem cells and fetal nervous system present differences in immunogenicity and immunomodulatory potentials in vitro. Stem Cell Res. 2013, 10, 325–337. [CrossRef] [PubMed]
28. Mittal, S.K.; Sharma, R.K.; Gupta, A.; Naik, S. Increased Interleukin-10 Production Without Expansion of CD4+CD25+ T-Regulatory Cells in Early Stable Renal Transplant Patients on Calcineurin Inhibitors. Transplantation 2009, 88, 435–441. [CrossRef]
29. Levitsky, J.; Gallon, L.; Miller, J.; Tambur, A.R.; Leventhal, J.; Flaa, C.; Huang, X.; Sarraj, B.; Wang, E.; Mathew, J.M. Allospecific Regulatory Effects of Sirolimus and Tacrolimus in the Human Mixed Lymphocyte Reaction. Transplantation 2011, 91, 199–206. [CrossRef]
30. Sakai, H.; Ishiyama, K.; Tanaka, Y.; Ide, K.; Ohira, M.; Tahara, H.; Abe, T.; Hirata, F.; Morimoto, H.; Hashimoto, S.; et al. Potential Benefit of Mixed Lymphocyte Reaction Assay-based Immune Monitoring After Living Donor Liver Transplantation for Recipients With Autoimmune Hepatitis. Transplant. Proc. 2014, 46, 785–789. [CrossRef]
31. Ozaki, M.; Iwanami, A.; Nagoshi, N.; Kohyama, J.; Itakura, G.; Iwai, H.; Nishimura, S.; Nishiyama, Y.; Kawabata, S.; Sugai, K.; et al. Evaluation of the immunogenicity of human iPS cell-derived neural stem/progenitor cells in vitro. Stem Cell Res. 2017, 19, 128–138. [CrossRef] [PubMed]
32. Miyamae, J.; Yagi, H.; Sato, K.; Okano, M.; Nishiya, K.; Katakura, F.; Sakai, M.; Nakayama, T.; Moritomo, T.; Shiina, T. Evaluation of alloreactive T cells based on the degree of MHC incompatibility using flow cytometric mixed lymphocyte reaction assay in dogs. Immunogenetics 2019, 71, 635–645. [CrossRef] [PubMed]
33. Colls, P.; Blanco, J.; Martínez-Pasarell, O.; Vidal, F.; Egozcue, J.; Márquez, C.; Guitart, M.; Templado, C. Chromosome segregation in a man heterozygous for a pericentric inversion, inv(9)(p11q13), analyzed by using sperm karyotyping and two-color fluorescence in situ hybridization on sperm nuclei. Hum. Genet. 1997, 99, 761–765. [CrossRef]
34. Jeong, S.Y.; Kim, B.Y.; Yu, J.E. De novo pericentric inversion of chromosome 9 in congenital anomaly. Yonsei Med. J. 2010, 51, 775–780. [CrossRef] [PubMed]
35. Barres, B.A.; Silverstein, B.E.; Corey, D.P.; Chun, L.L.Y. Immunological, morphological, and electrophysiological variation among retinal ganglion cells purified by panning. Neuron 1988, 1, 791–803. [CrossRef]
36. Kobayashi, W.; Onishi, A.; Tu, H.-Y.; Takihara, Y.; Matsumura, M.; Tsujimoto, K.; Inatani, M.; Nakazawa, T.; Takahashi, M. Culture Systems of Dissociated Mouse and Human Pluripotent Stem Cell–Derived Retinal Ganglion Cells Purified by Two-Step Immunopanning. Invest. Ophthalmol. Vis. Sci. 2018, 59, 776–787. [CrossRef]
37. Green, D.R.; Ferguson, T.A. The role of fas ligand in immune privilege. Nat. Rev. Mol. Cell Biol. 2001, 2, 917–924. [CrossRef]
38. Sharpe, A.H.; Freeman, G.J. The B7–CD28 superfamily. Nat. Rev. Immunol. 2002, 2, 116–126. [CrossRef]
39. Schoenborn, J.R.; Wilson, C.B. Regulation of Interferon-γ During Innate and Adaptive Immune Responses. Adv. Immunol. 2007, 96, 41–101.
40. Fujii, S.; Yoshida, S.; Inagaki, E.; Hatou, S.; Tsubota, K.; Takahashi, M.; Shimmura, S.; Sugita, S. Immunological Properties of Neural Crest Cells Derived from Human Induced Pluripotent Stem Cells. Stem Cells Dev. 2019, 28, 28–43. [CrossRef]
41. Gao, W.; Demirci, G.; Strom, T.B.; Li, X.C. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation 2003, 76, 994–999. [CrossRef] [PubMed]
42. Ozkaynak, E.; Wang, L.; Goodearl, A.; McDonald, K.; Qin, S.; O’Keefe, T.; Duong, T.; Smith, T.; Gutierrez-Ramos, J.C.; Rottman, J.B.; et al. Programmed Death-1 Targeting Can Promote Allograft Survival. J. Immunol. 2002, 169, 6546–6553. [CrossRef] [PubMed]
43. Horie, S.; Sugita, S.; Futagami, Y.; Kawaguchi, T.; Kamoi, K.; Shirato, S.; Mochizuki, M. Human iris pigment epithelium suppresses activation of bystander T cells via TGFβ–TGFβ receptor interaction. Exp. Eye Res. 2009, 88, 1033–1042. [CrossRef] [PubMed]
44. Yamada, Y.; Sugita, S.; Horie, S.; Yamagami, S.; Mochizuki, M. Mechanisms of Immune Suppression for CD8+T Cells by Human Corneal Endothelial Cells via Membrane-Bound TGFβ. Invest. Ophthalmol. Vis. Sci. 2010, 51, 2548–2557. [CrossRef] [PubMed]
45. Sheibani, N.; Sorenson, C.M.; Cornelius, L.A.; Frazier, W.A. Thrombospondin-1, a Natural Inhibitor of Angiogenesis, Is Present in Vitreous and Aqueous Humor and Is Modulated by Hyperglycemia. Biochem. Biophys. Res. Commun. 2000, 267, 257–261. [CrossRef]
46. Lawler, J. The functions of thrombospondin-1 and-2. Curr. Opin. Cell Biol. 2000, 12, 634–640. [CrossRef]
47. Taylor, A.W.; Yee, D.G. Somatostatin Is an Immunosuppressive Factor in Aqueous Humor. Invest. Ophthalmol. Vis. Sci. 2003, 44, 2644–2649. [CrossRef]
48. Taylor, A.W. A review of the influence of aqueous humor on immunity. Ocul. Immunol. Inflamm. 2003, 11, 231–241. [CrossRef]
49. Streilein, J.W. Ocular immune privilege: Therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 2003, 3, 879–889. [CrossRef]
50. Stein-Streilein, J. Mechanisms of immune privilege in the posterior eye. Int. Rev. Immunol. 2013, 32, 42–56. [CrossRef] [PubMed]
51. Murphy-Ullrich, J.E.; Suto, M.J. Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease. Matrix Biol. 2018, 68–69, 28–43. [CrossRef] [PubMed]
52. Wenkel, H.; Streilein, J.W. Analysis of immune deviation elicited by antigens injected into the subretinal space. Invest. Ophthalmol. Vis. Sci. 1998, 39, 1823–1834.
53. Sonoda, K.-H.; Sakamoto, T.; Qiao, H.; Hisatomi, T.; Oshima, T.; Tsutsumi-Miyahara, C.; Exley, M.; Balk, S.P.; Taniguchi, M.; Ishibashi, T. The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: Vitreous cavity-associated immune deviation. Immunology 2005, 116, 390–399. [CrossRef] [PubMed]
54. Sugita, S.; Makabe, K.; Fujii, S.; Iwasaki, Y.; Kamao, H.; Shiina, T.; Ogasawara, K.; Takahashi, M. Detection of Retinal Pigment Epithelium-Specific Antibody in iPSC-Derived Retinal Pigment Epithelium Transplantation Models. Stem Cell Rep. 2017, 9, 1501–1515. [CrossRef] [PubMed]
55. McGill, T.J.; Stoddard, J.; Renner, L.M.; Messaoudi, I.; Bharti, K.; Mitalipov, S.; Lauer, A.; Wilson, D.J.; Neuringer, M. Allogeneic iPSC-Derived RPE Cell Graft Failure Following Transplantation Into the Subretinal Space in Nonhuman Primates. Invest. Ophthalmol. Vis. Sci. 2018, 59, 1374–1383. [CrossRef]
56. Fujii, S.; Sugita, S.; Futatsugi, Y.; Ishida, M.; Edo, A.; Makabe, K.; Kamao, H.; Iwasaki, Y.; Sakaguchi, H.; Hirami, Y.; et al. A Strategy for Personalized Treatment of iPS-Retinal Immune Rejections Assessed in Cynomolgus Monkey Models. Int. J. Mol. Sci. 2020, 21, 3077. [CrossRef]
57. Sugita, S.; Iwasaki, Y.; Makabe, K.; Kamao, H.; Mandai, M.; Shiina, T.; Ogasawara, K.; Hirami, Y.; Kurimoto, Y.; Takahashi, M. Successful Transplantation of Retinal Pigment Epithelial Cells from MHC Homozygote iPSCs in MHC-Matched Models. Stem Cell Rep. 2016, 7, 635–648. [CrossRef]
58. Okita, K.; Yamakawa, T.; Matsumura, Y.; Sato, Y.; Amano, N.; Watanabe, A.; Goshima, N.; Yamanaka, S. An Efficient Nonviral Method to Generate Integration-Free Human-Induced Pluripotent Stem Cells from Cord Blood and Peripheral Blood Cells. Stem Cells 2013, 31, 458–466. [CrossRef]
59. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861–872. [CrossRef]
60. Nakagawa, M.; Taniguchi, Y.; Senda, S.; Takizawa, N.; Ichisaka, T.; Asano, K.; Morizane, A.; Doi, D.; Takahashi, J.; Nishizawa, M.; et al. A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. Sci. Rep. 2014, 4, 3594. [CrossRef]